Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
United Therapeutic
(NQ:
UTHR
)
344.98
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about United Therapeutic
< Previous
1
2
3
4
5
6
Next >
UroGen Pharma Stock Earns 91 RS Rating
June 27, 2024
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.
Via
Investor's Business Daily
When you look at NASDAQ:UTHR, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
June 26, 2024
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
Arcellx Stock Earns Relative Strength Rating Upgrade
June 21, 2024
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.
Via
Investor's Business Daily
The 3 Best Medical Device Stocks to Buy in June 2024
June 20, 2024
Medical devices are at the forefront of the digitalization of medicine. making these the three best medical device stocks to buy.
Via
InvestorPlace
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
June 20, 2024
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
June 19, 2024
Via
Benzinga
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (5 Ratings)
June 12, 2024
Via
Benzinga
Expert Ratings For United Therapeutics
May 21, 2024
Via
Benzinga
The Latest Analyst Ratings For United Therapeutics
May 02, 2024
Via
Benzinga
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
June 14, 2024
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas.
Via
Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
June 12, 2024
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.
Via
Investor's Business Daily
Krystal Biotech Stock Sees RS Rating Jump To 91
June 11, 2024
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
June 11, 2024
Via
Benzinga
Halozyme Therapeutics Scores RS Rating Jump To 91
June 07, 2024
On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91.
Via
Investor's Business Daily
For those who appreciate value investing, NASDAQ:UTHR is a compelling option with its solid fundamentals.
June 05, 2024
Investors should take notice ofUNITED THERAPEUTICS CORP (NASDAQ:UTHR)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024
June 04, 2024
Seeking discounts in relevant places makes sense and there are few arenas more compelling than undervalued healthcare stocks.
Via
InvestorPlace
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics
June 03, 2024
Liquidia stock retook its 50-day line Monday on a U.S. judge's ruling on a patent dispute with fellow biotech company United Therapeutics.
Via
Investor's Business Daily
Topics
Intellectual Property
Exposures
Intellectual Property
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 20, 2024
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.
Via
InvestorPlace
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
May 16, 2024
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.
Via
Investor's Business Daily
NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
May 15, 2024
UNITED THERAPEUTICS CORP (NASDAQ:UTHR), an undervalued stock with good fundamentals.
Via
Chartmill
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
May 14, 2024
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.
Via
Investor's Business Daily
3 Biotech Stocks to Double Your Money in the Next 24 Months
May 06, 2024
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates.
Via
InvestorPlace
Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity
May 01, 2024
United Therapeutics impresses with record-breaking Q1 results. Revenue soars 34% Y/Y to $677.7 million, EPS jumps to $6.17. Tyvaso leads the charge with a 56% revenue surge.
Via
Benzinga
UTHR Stock Earnings: United Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 01, 2024
UTHR stock results show that United Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday
May 01, 2024
Via
Benzinga
NASDAQ:UTHR stands out as a stock that provides good value for the fundamentals it showcases.
April 24, 2024
Despite its impressive fundamentals, UNITED THERAPEUTICS CORP (NASDAQ:UTHR) remains undervalued.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
March 26, 2024
Via
Benzinga
The Bargain Hunter’s Portfolio: 7 Smart Stock Buys for the Shrewd Investor
March 25, 2024
Although several companies have seen their valuations blossom, you can still find bargain stocks if you know where to look.
Via
InvestorPlace
The 3 Most Undervalued Nasdaq Stocks to Buy in March 2024
March 13, 2024
Learn about these undervalued NASDAQ stocks teeming with the potential to bounce back and show great returns for investors this year.
Via
InvestorPlace
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
March 05, 2024
These three companies represent the world of biotech stocks and offer a unique blend of high risk and potentially high reward.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.